FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy
FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Cheng, Yu [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022transfer abstract |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides - Nigolian, H. ELSEVIER, 2022, New York, NY [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:611 ; year:2022 ; day:5 ; month:01 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.ijpharm.2021.121349 |
|---|
| Katalog-ID: |
ELV056262663 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056262663 | ||
| 003 | DE-627 | ||
| 005 | 20230626043018.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijpharm.2021.121349 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica |
| 035 | |a (DE-627)ELV056262663 | ||
| 035 | |a (ELSEVIER)S0378-5173(21)01155-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.61 |2 bkl | ||
| 100 | 1 | |a Cheng, Yu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy |
| 264 | 1 | |c 2022transfer abstract | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. | ||
| 520 | |a FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. | ||
| 650 | 7 | |a Glucose oxidase |2 Elsevier | |
| 650 | 7 | |a Chemodynamic therapy |2 Elsevier | |
| 650 | 7 | |a Targeted therapy |2 Elsevier | |
| 650 | 7 | |a Starvation therapy |2 Elsevier | |
| 650 | 7 | |a Ferrocene |2 Elsevier | |
| 700 | 1 | |a Ji, Yuanhui |4 oth | |
| 700 | 1 | |a Ouyang, Defang |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Nigolian, H. ELSEVIER |t Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |d 2022 |g New York, NY [u.a.] |w (DE-627)ELV008932840 |
| 773 | 1 | 8 | |g volume:611 |g year:2022 |g day:5 |g month:01 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.ijpharm.2021.121349 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.61 |j Innere Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 611 |j 2022 |b 5 |c 0105 |h 0 | ||
| author_variant |
y c yc |
|---|---|
| matchkey_str |
chengyujiyuanhuiouyangdefang:2022----:cbidnueguoexdsnndusotree |
| hierarchy_sort_str |
2022transfer abstract |
| bklnumber |
44.61 |
| publishDate |
2022 |
| allfields |
10.1016/j.ijpharm.2021.121349 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica (DE-627)ELV056262663 (ELSEVIER)S0378-5173(21)01155-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.61 bkl Cheng, Yu verfasserin aut FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene Elsevier Ji, Yuanhui oth Ouyang, Defang oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:611 year:2022 day:5 month:01 pages:0 https://doi.org/10.1016/j.ijpharm.2021.121349 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 611 2022 5 0105 0 |
| spelling |
10.1016/j.ijpharm.2021.121349 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica (DE-627)ELV056262663 (ELSEVIER)S0378-5173(21)01155-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.61 bkl Cheng, Yu verfasserin aut FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene Elsevier Ji, Yuanhui oth Ouyang, Defang oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:611 year:2022 day:5 month:01 pages:0 https://doi.org/10.1016/j.ijpharm.2021.121349 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 611 2022 5 0105 0 |
| allfields_unstemmed |
10.1016/j.ijpharm.2021.121349 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica (DE-627)ELV056262663 (ELSEVIER)S0378-5173(21)01155-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.61 bkl Cheng, Yu verfasserin aut FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene Elsevier Ji, Yuanhui oth Ouyang, Defang oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:611 year:2022 day:5 month:01 pages:0 https://doi.org/10.1016/j.ijpharm.2021.121349 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 611 2022 5 0105 0 |
| allfieldsGer |
10.1016/j.ijpharm.2021.121349 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica (DE-627)ELV056262663 (ELSEVIER)S0378-5173(21)01155-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.61 bkl Cheng, Yu verfasserin aut FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene Elsevier Ji, Yuanhui oth Ouyang, Defang oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:611 year:2022 day:5 month:01 pages:0 https://doi.org/10.1016/j.ijpharm.2021.121349 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 611 2022 5 0105 0 |
| allfieldsSound |
10.1016/j.ijpharm.2021.121349 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica (DE-627)ELV056262663 (ELSEVIER)S0378-5173(21)01155-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.61 bkl Cheng, Yu verfasserin aut FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy 2022transfer abstract nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene Elsevier Ji, Yuanhui oth Ouyang, Defang oth Enthalten in Elsevier Nigolian, H. ELSEVIER Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides 2022 New York, NY [u.a.] (DE-627)ELV008932840 volume:611 year:2022 day:5 month:01 pages:0 https://doi.org/10.1016/j.ijpharm.2021.121349 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.61 Innere Medizin VZ AR 611 2022 5 0105 0 |
| language |
English |
| source |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:611 year:2022 day:5 month:01 pages:0 |
| sourceStr |
Enthalten in Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides New York, NY [u.a.] volume:611 year:2022 day:5 month:01 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Innere Medizin |
| institution |
findex.gbv.de |
| topic_facet |
Glucose oxidase Chemodynamic therapy Targeted therapy Starvation therapy Ferrocene |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| authorswithroles_txt_mv |
Cheng, Yu @@aut@@ Ji, Yuanhui @@oth@@ Ouyang, Defang @@oth@@ |
| publishDateDaySort_date |
2022-01-05T00:00:00Z |
| hierarchy_top_id |
ELV008932840 |
| dewey-sort |
3610 |
| id |
ELV056262663 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056262663</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626043018.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2021.121349</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056262663</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(21)01155-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Cheng, Yu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glucose oxidase</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemodynamic therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Targeted therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Starvation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ferrocene</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ji, Yuanhui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ouyang, Defang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:611</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:5</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2021.121349</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">611</subfield><subfield code="j">2022</subfield><subfield code="b">5</subfield><subfield code="c">0105</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Cheng, Yu |
| spellingShingle |
Cheng, Yu ddc 610 bkl 44.61 Elsevier Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy |
| authorStr |
Cheng, Yu |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV008932840 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.61 bkl FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene Elsevier |
| topic |
ddc 610 bkl 44.61 Elsevier Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene |
| topic_unstemmed |
ddc 610 bkl 44.61 Elsevier Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene |
| topic_browse |
ddc 610 bkl 44.61 Elsevier Glucose oxidase Elsevier Chemodynamic therapy Elsevier Targeted therapy Elsevier Starvation therapy Elsevier Ferrocene |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
y j yj d o do |
| hierarchy_parent_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| hierarchy_parent_id |
ELV008932840 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV008932840 |
| title |
FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy |
| ctrlnum |
(DE-627)ELV056262663 (ELSEVIER)S0378-5173(21)01155-8 |
| title_full |
FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy |
| author_sort |
Cheng, Yu |
| journal |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| journalStr |
Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Cheng, Yu |
| container_volume |
611 |
| class |
610 VZ 44.61 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Cheng, Yu |
| doi_str_mv |
10.1016/j.ijpharm.2021.121349 |
| dewey-full |
610 |
| title_sort |
fc-bbr/ind-induced glucose oxidase nanodrugs for targeted combination therapy |
| title_auth |
FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy |
| abstract |
FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. |
| abstractGer |
FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. |
| abstract_unstemmed |
FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy |
| url |
https://doi.org/10.1016/j.ijpharm.2021.121349 |
| remote_bool |
true |
| author2 |
Ji, Yuanhui Ouyang, Defang |
| author2Str |
Ji, Yuanhui Ouyang, Defang |
| ppnlink |
ELV008932840 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.ijpharm.2021.121349 |
| up_date |
2024-07-06T19:53:24.901Z |
| _version_ |
1803860684205719552 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056262663</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626043018.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.ijpharm.2021.121349</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001984.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056262663</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0378-5173(21)01155-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.61</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Cheng, Yu</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">FC-BBR/IND-induced glucose oxidase nanodrugs for targeted combination therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022transfer abstract</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">FC-BBR and IND induced glucose oxidase (GOD) to self-assemble, which was then encapsulated by HA to form nanodrugs (FC-BBR/INDGOD@HA NPs). The prepared nanoassembly could inhibit the proliferation and induce the apoptosis of HepG2 cells, which might be the result of targeted chemodynamic therapy and starvation therapy mediated by HA and BBR. Moreover, the FC-BBR/IND@GOD@HA NPs could also reduce the mitochondrial membrane potential, increase the level of reactive oxygen species and block cells in S phase. More importantly, it could inhibit the movement and migration of cancer cells, which gave it the potential to prevent tumor metastasis.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Glucose oxidase</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Chemodynamic therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Targeted therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Starvation therapy</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ferrocene</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ji, Yuanhui</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Ouyang, Defang</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Nigolian, H. ELSEVIER</subfield><subfield code="t">Description d’une cohorte française multicentrique de porteurs asymptomatiques d’anticorps anti-phospholipides</subfield><subfield code="d">2022</subfield><subfield code="g">New York, NY [u.a.]</subfield><subfield code="w">(DE-627)ELV008932840</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:611</subfield><subfield code="g">year:2022</subfield><subfield code="g">day:5</subfield><subfield code="g">month:01</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.ijpharm.2021.121349</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.61</subfield><subfield code="j">Innere Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">611</subfield><subfield code="j">2022</subfield><subfield code="b">5</subfield><subfield code="c">0105</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.400448 |